急性心肌梗死患者血浆TAT变化的价值  

Significance of Changes of Plasma Thrombin-antithrombin Complex in Patients with Acute Myocardial Infarction

作　　者：沈培辰[1] 张代富[1] 王娟[1] 马兰[1] 

机构地区：[1]上海同济大学附属东方医院心血管内科,200120

出　　处：《实用全科医学》2005年第6期477-478,共2页Applied Journal Of General Practice

摘　　要：目的观察急性心肌梗死(AMI)患者溶栓治疗前后血浆凝血酶-抗凝血酶复合物(TAT)的变化。方法AMI患者34例,对照33例,采用双抗体夹心法检测血浆TAT;对其中6例患者溶栓前、溶栓后6 h及对12 h的血浆TAT进行动态观察,与对照组进行比较。结果AMI组TAT[(13.10±6.70)μg/l]较对照组[(6.96±3.60)μg/l]显著升高(P<0.01);6例溶栓治疗的患者;溶栓6 h后,TAT[(15.10±7.60)μg/l]较治疗前显著升高(P<0.05)。结论TAT是AMI早期诊断、治疗及预后判断的良好指标之一。Objective To observe the changes of plasma thrombin - antithrombin complex （TAT） in patients with acute myocardial infarction （AMI） before and after intravenous thrombolytic treatment. Methods TAT level was determined by ELISA in 34 patients with AMI and 33 nomal controls. TAT was serially evaluated on admission, 6 h and 12 h after thrombolytic treatment in 6cases with AMI. The results were compared with control, Results The plasma TAT level in cases with AMI increased significantly compared with the control. TAT increased more significantly 6h after the thrombolysis. There was no significant difference in the TAT level between 12h after thrombolysis and before treatment. But it was still higher than control. Conclusions Plasma TAT is one of the good markers for AMI early diagnosis, treatment and prognosis.

关 键 词：急性心肌梗死 血浆 凝血酶-抗凝血酶复合物 肌红蛋白 纤维蛋白 纤溶酶原 

分 类 号：R542.22[医药卫生—心血管疾病]